Lupin Q1 FY27 Results (NSE: LUPIN)
Signal: Margin expansion
The read
The trajectory remains constructive: consolidated EBITDA margin expanded 190bps YoY to 31.2% after eight consecutive quarters of expansion, supported by gross-margin expansion to 74.6% and employee-cost intensity falling to 16.8%; however, PAT growth was limited to 16.0% as the tax rate normalized, and the 51.5% rise in depreciation warrants monitoring.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹8,276.9 Cr | +32.0% | +10.7% |
| EBIT | ₹2,127 Cr | +41.1% | |
| Net profit | ₹1,417 Cr | +16.0% | |
| EPS | ₹30.95 | +16.0% | |
| EBIT margin | 31.2% |
P&L walk
Revenue increased 32.0% YoY and 10.7% QoQ, while gross margin expanded 330bps YoY to 74.6%; EBITDA margin rose 190bps YoY to 31.2%, but PAT growth of 16.0% lagged PBT growth of 42.5% because tax increased 209.5% YoY.
Segments
The U.S. was the largest growth engine at ₹34,348 million, up 42.9% YoY, while Other Developed Markets grew 48.3% and Emerging Markets 51.7%; India grew more steadily at 13.9% but accelerated 24.7% QoQ.
Key positives
- Gross margin expanded 330bps YoY to 74.6% as material cost fell to 25.4% of sales from 28.7%; the filing does not disclose whether this was driven by input deflation, pricing or mix.
- U.S. sales rose 42.9% YoY to ₹34,348 million and represented 42% of global sales; Lupin received 6 ANDA approvals and launched 3 products during the quarter.
- EBITDA grew 42.8% YoY to ₹25,799 million versus revenue growth of 32.0%, while employee cost grew 27.7% and declined to 16.8% of sales from 17.6%.
- R&D investment increased 22.1% YoY to ₹6,077 million while R&D intensity declined to 7.4% of sales from 8.1%, and the company reported 50 first-to-file filings including 21 exclusive opportunities.
- The company held net cash of ₹28,308 million and generated broad-based formulation growth, with Other Developed Markets up 48.3% and Emerging Markets up 51.7% YoY.
Key concerns
- PAT grew only 16.0% YoY to ₹14,170 million versus PBT growth of 42.5% because tax increased 209.5% to ₹6,004 million, making bottom-line growth less representative of operating momentum.
- Depreciation, amortization and impairment rose 51.5% YoY to ₹4,529 million, materially faster than revenue growth and reducing EBITDA-to-EBIT conversion.
- Consolidated EBITDA margin of 31.2% was 22.3 percentage points below the 53.5% standalone margin, showing that subsidiaries and other group entities materially dilute group profitability.
- API sales grew only 8.5% YoY to ₹2,637 million, substantially below total product-sales growth of 33.3%.
Research and educational content only. Not investment advice.